Idorsia gets FDA approval of Tryvio (aprocitentan) for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that use.

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.